<!DOCTYPE html>
<html>
	<head>
		<link rel="stylesheet" href="main.css">
		<title>ME/CFS Research</title>
	</head>
	<body>
		<div class="main">
			<h1><a href="/">ME/CFS Research</a> :: Treatments</h1>
			<hr class="styled top">
			<div class="main-column">
				<h2>Treatments</h2>
				<p class="passage">
					The following are trialed, proposed, hypothetical, speculative, or imaginary treatments
					for ME/CFS
					These are not meant as treatments for patients to try but ideas for further research and
					maybe clinical trials. Drugs that have undergone trials will also be included.
				</p>

<h4><u>Proposed or Speculative Repurposed Drugs</u></h4>
<ul>
	<li>For Orthostatic Hypotension and/or Exercise Intolerance
		<ul>
			<li><span class="drug-name">droxidopa</span> (Northera)</li>
			<li><span class="drug-name">midodrine</span></li>
			<li><span class="drug-name">fludrocortisone</span></li>
			<li><span class="drug-name">pyridostigmine</span> (Mestinon)</li>
		</ul>
	</li>
	<li>For Cerebral Blood Flow
		<ul>
			<li><span class="drug-name">sildenafil</span> (Viagra)
				<ul>
					<li><a href="https://grantome.com/grant/NIH/P20-RR011145-14S2-6918">hypothesis</a></li>
					<li><a href="https://clinicaltrials.gov/study/NCT00598585">clinical trial completed</a></li>
					<li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9127063/">improvement of neurologic and endothelial function and inflammation after brain injury</a></li>
					<li><a href="https://journals.lww.com/clinicalneuropharm/abstract/2008/11000/role_of_sildenafil_in_neurological_disorders.6.aspx">neurological adverse events</a></li>
					<li><a href="https://x.com/organichemusic/status/1591421636154204160">X discussion</a></li>
				</ul>
			</li>
		</ul>
	</li>
	<li>low dose <span class="drug-name">naltrexone</span> (LDN) â€“ possible immune modulator, has other effects</li>
	<li>low dose <span class="drug-name">aripiprazole</span> (Abilify)</li>
	<li>Immunomodulators/Monoclonal Antibodies
		<ul>
			<li><span class="drug-name">rituximab</span> (successful Phase II trial, failed Phase III trial)</li>
			<li><span class="drug-name">cyclophosphamide</span> (Fluge & Mella)</li>
			<li><span class="drug-name">daratumumab</span> (Fluge & Mella)</li>
			<li>
				next-generation B cell-depleting anti-CD20 antibodies<br>
				(proposed in Robinson 2024 for systemic autoimmune diseases,
				these deplete both blood and tissue B cells more efficiently than rituximab)
				<ul>
					<li><span class="drug-name">obinutuzumab</span>, <span class="drug-name">ocrelizumab</span> or <span class="drug-name">ofatumumab</span></li>
				</ul>
			</li>
			<li>subcutaneous <span class="drug-name">ofatumumab</span> (Kesimpta) (for better tissue penetration)</li>
			<li><span class="drug-name">rapamycin</span> (siroliums/Rapamune) (D Peterson)
				(<a href="https://clinicaltrials.gov/study/NCT06257420">clinical trial ongoing</a>)
			</li>
			<li>JAK inhibitors, e.g. <span class="drug-name">tofacitinib</span> (Xeljanz) and <span class="drug-name">baricitinib</span> (Olumiant)</li>
			<li><span class="drug-name">abatacept</span> or <span class="drug-name">belatacept</span> (inhibit T cell activation)</li>
			<li>checkpoint inhibitors (to clear peristent pathogens; might cause autoimmunity or rheumatic disease)
			</li>
			<li><span class="drug-name">IVIG</span></li>
			<li><span class="drug-name">leflunomide</span> or <span class="drug-name">teriflunomide</span> (anti-rheumatic/immune suppressant/anti-EBV)
				<ul>
					<li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5546479/">Bilger 2017</a> - inhibits EBV replication</li>
				</ul>
			</li>
		</ul>
	</li>
	<li>
		Antivirals (new trials should be a minimum 9 months, but preferably a minimum 12 months)
		<ul>
			<li style="font-style:italic">General and comparative research
				<ul>
					<li><a href="https://pubmed.ncbi.nlm.nih.gov/15130535/">Friedrichs 2004</a> - Comparison of antivirals against EBV in vitro with PCR</li>
					<li><a href="https://pubmed.ncbi.nlm.nih.gov/32409608/">Drosu 2020</a> - Test of tenofovir and other drugs against EBV in vitro</li>
				</ul>
			</li>
			<li>valacyclovir (Valtrex)
				<ul>
					<li><a href="https://pubmed.ncbi.nlm.nih.gov/18019402/">Lerner 2007</a> - clinical trial in CFS</li>
					<li><a href="https://pubmed.ncbi.nlm.nih.gov/19740997/">Hoshino 2009</a> - reduced latent EBV infected B cells in healthy subjects</li>
				</ul>
			</li>
			<li>famciclovir (Famvir) - similar efficacy as valacyclovir, less neurotoxicity</li>
			<li>valganciclovir (Valcyte)
				<ul>
					<li><a href="https://pubmed.ncbi.nlm.nih.gov/23959519/">Montoya 2013</a> - clinical trial in CFS</li>
					<li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5854009/">Yager 2017</a> - reduced saliva EBV shedding in healthy subjects</a></li>
				</ul>
			</li>
			<li>cidofovir (Vistide) - intravenous antiviral</li>
			<li>brincidofovir (Tembexa / CMX001) - oral cidofovir prodrug</li>
			<li>artesunate - injection or oral?</li>
			<li>tenofovir disoproxil fumarate (speculative)</li>
			<li>tenofovir alafenamide (speculative) - better tissue penetration and lower toxicity</li>
			<li>metformin - for SARS-CoV-2 in Long COVID (<a href="https://pubmed.ncbi.nlm.nih.gov/38690892/">Bramante 2024</a>)</li>
		</ul>
	</li>
	<li>
		Vitamins and Supplements
		<ul>
			<li>Thiamine (<a href="https://doi.org/10.1016/j.gastha.2024.08.012">IBD-associated fatigue trial</a>)</li>
		</ul>
	</li>
</ul>

<h4 style="text-align: left;"><u>Proposed or Speculative Combination Protocols</u></h4>
<ul>
    <li>LDN + pyridostigmine (proposed by D Systrom, <a href="https://clinicaltrials.gov/study/NCT06366724">clinical trial ongoing</a>)</li>
    <li>rituximab + anti-EBV drug (<a href="https://www.youtube.com/watch?v=jJFt2EWG58c">proposed by T Craddock, N Klimas</a> - no known plans for trial)</li>
    <li>rituximab + IVIG (<a href="https://pubmed.ncbi.nlm.nih.gov/30072982/">proposed by A Ahmed</a> - for generalized autoimmune disease)</li>
	<li>EBV reactivation + anti-EBV drug (highly speculative, could worsen autoimmunity)
		<ul>
			<li>EBV reactivation agents:
				<ul>
					<li>valproic acid / sodium valproate</li>
					<li>sodium butyrate - not bioavailable; butyrate-producing probiotics?</li>
				</ul>
			</li>
		</ul>
	</li>
  <li>bone marrow transplant (highly speculative, risky)</li>
</ul>


<h4 style="text-align: left;"><u>Under Development</u></h4>
<ul>
	<li>Berlin Cures BC007</li>
	<li>Mitodicure MDC002</li>
	<li>Inspiritol (nebulized inhaled glutathione and other ingredients)</li>
	<li>WinSanTor WST057 (topical pirenzepine) (being developed for peripheral neuropathy)</li>
	<li>Ampligen (rintintolimod / poly i:poly c12u)</li>
    <li>Immunoadsorption (trial in Germany)</li>
</ul>

<h4 style="text-align: left;"><u>Imaginary</u></h4>
<ul>
  <li>Anti-CD21 antibody (to eliminate EBV infected cells and vulnerable cells)</li>
</ul>

				<h2>Editor's Comment</h2>
				<p class="passage">
					<b>On rituximab</b>: A promising pilot study in three patients led to a small double-blind placebo-controlled
					trial of rituximab in ME/CFS, which was successful. However, a larger follow-up study was negative.
					It is interesting to note that the three pilot patients all had ME/CFS triggered by EBV, and some had lymphoma.
					The question remains whether rituximab might work better in a carefully selected subgroup of patients &ndash;
					perhaps those whose illness was triggered by EBV, or who have comorbid autoimmune conditions, lymphoma, or
					maybe prolonged lymphadenopathy, which might be considered pre-lymphoma.
				</p>
				<p class="passage">
					<b>On antivirals</b>: Clinical trials of antivirals in ME/CFS have generally led to small, but underwhelming results
					(trials of antivirals in multiple sclerosis, believed to be caused by Epstein-Barr virus, have also lead to marginal benefit).
					Longer-duration trials (at least 12 months) and/or combination with immunomodulatory drugs are possible avenues to
					explore in the future. Measurement of EBV latent viral load, such as in Hoshino 2012, or saliva shedding, such as
					in Yager 2017, could improve understanding and interpretation of results.
					<a href="https://www.youtube.com/watch?v=jJFt2EWG58c">T Craddock/N Klimas</a> argue that EBV from
					epithelial cells may serve as a kind of (editor's words) "co-reservoir," with B cells and other immune cells, making it
					necessary to target the virus from multiple angles in order to successfully reduce the viral load.
					Other research has pointed to increased latent replication of EBV in ME/CFS patients, which cannot be targeted
					by current antiviral drugs.
				</p>


			</div>
			<hr class="styled bottom">
			<p style="text-align:right; padding: 0; margin:0; font-size:80%;">Last Update: 21 October 2024</p>
		</div>
	</body>
</html>
